Expanding patent portfolio reinforces the Company's commitment to wound care innovation, with 55 issued patents and 52 pending applications Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, a ...

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T. Investor Contact: Christina Tartaglia Precision AQ 332.322.7430 Christina.tartaglia@precisionaq.com Media Contact: Peg Rusconi 6 ...

MONTREAL, May 28, 2025 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX.V: HAR) ("Harfang" or the "Company") is pleased to announce additional high-grade intercepts and the second batch of results from the 2025 winter diamond drill program ("Winter Drilling"). Winter Drilling focused on the Koval patented claims at its recently acquired and wholly owned Sky Lake Gold Project located in Ontario's Pickle Lake Gold District (Figure 1). The Company has intersected a high-grade mineralized interval interpreted ...

About 303 Study 303 Study is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical C ...

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical- stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT. A webcast of the fireside chat will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.mon ...

SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the "Board") on May 27, 2025 approved a One-for- Thirty (1-for-30) reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company's ...

Prestigious Global Certification Expected to Accelerate Strategic Supply Relationships with Major Auto OEMs and Distributors West Seneca, New York, May 28, 2025 (GLOBE NEWSWIRE) -- Worksport Ltd. (NASDAQ: WKSP) ("Worksport" or the "Company"), a U.S.-based innovator and manufacturer of premium tonneau covers and clean-energy solutions, proudly announces that its U.S. production facility has officially achieved ISO 9001:2015 certification. This milestone strengthens Worksport's manufacturing credentials and i ...

CAMARILLO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company, Inc. (NASDAQ: NWTG), a technology-driven golf shaft manufacturer, today announced that it has received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market. The confirmation from Nasdaq follows Newton Golf's filing of i ...

SOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026 These two complementary trials are intended to form the basis of an NDA submission of AXPAXLI in wet AMD BEDFORD, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced that ...

Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com Kris Fortner Nurix Therapeutics Kfortner@nurixtx.com Contacts: Investors Kris Fortner Nurix Therapeutics, Inc. kfortner@nurixtx.com Elizabeth Wolffe, Ph.D. Wheelhouse Life Science Advisors lwolffe@wheelhouselsa.com Media SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein d ...